Search Results for

Showing 1 - 2 of 2 results
  1. Spotlight on members: Spark

    Spotlight on members From hospital funding to FDA approval Spark Therapeutics develops gene therapy for inherited retinal blindness After over two decades of research and development in gene therapy, Katherine A. High, MD, co-founder, president and chief scientific officer of Spark Therapeutics, is breathing a big sigh of relief this fall. On Oct. 12, the Food and Drug Administration unanimously voted to approve voretigene neparvovec, Spark Therapeutics' gene therapy treatment for inherited b

  2. Journals and Publications landing

    Journals and Publications ARVO Journals           Visit the ARVO Funding Guide and search through 200+ funding opportunities in the fields of eye and vision research.  ARVO Funding Guide ARVONews ARVO Insight